NDAS

HyreCar Retains Northland Capital Markets as Advisor to Explore Strategic Alternatives

Retrieved on: 
Lunedì, Febbraio 6, 2023

LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- HyreCar Inc. (OTC: HYRE) (“HyreCar” or the “Company”), the carsharing marketplace for ridesharing and food and package delivery services, today announced that, pursuant to its previously disclosed process to evaluate potential strategic alternatives meant to maximize shareholder value for the Company, the Company’s board of directors (the “Board”) has retained Northland Capital Markets (“Northland”) as its financial advisor.

Key Points: 
  • LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- HyreCar Inc. (OTC: HYRE) (“HyreCar” or the “Company”), the carsharing marketplace for ridesharing and food and package delivery services, today announced that, pursuant to its previously disclosed process to evaluate potential strategic alternatives meant to maximize shareholder value for the Company, the Company’s board of directors (the “Board”) has retained Northland Capital Markets (“Northland”) as its financial advisor.
  • With assistance from Northland and its other advisors, the Board will assess a full range of strategic alternatives, including a sale, merger, divestiture, recapitalization, going private transaction, additional financing, and other significant transactions.
  • To date, the Company has received multiple executed NDAs in consideration of a potential transaction or strategic partnership.
  • The Board has not set a timetable for the conclusion of its evaluation of strategic alternatives and has not made any decisions related to strategic alternatives at this time.

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

Retrieved on: 
Mercoledì, Gennaio 11, 2023

CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.

Key Points: 
  • Mickle, M.A., to Chief Product Development Officer.
  • Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.
  • Dr. Guenther was one of the first members of KemPharm, most recently serving as the company’s Executive Vice President of Research and Development.
  • As Chief Scientific Officer, he will continue to lead KemPharm’s research team and play a central role in the advancement of the company’s pipeline.

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Martedì, Gennaio 3, 2023

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.

Key Points: 
  • SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.
  • The presentation will be made by Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • Details of the event are as follow:
    An archived version of the presentation also will be available on the Company website following the live presentation.
  • You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect.

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Martedì, Dicembre 27, 2022

SHANGHAI and HONG KONG, Dec. 26, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) on a multicenter, open-label, Phase I dose-finding study of ATG-037 as a monotherapy and in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with locally advanced or metastatic solid tumors (the STAMINA-001 study).

Key Points: 
  • Secondary objectives of the study include the characterization of the pharmacology and evaluation of preliminary efficacy of ATG-037.
  • Under the terms of the Agreement, the study will be conducted by Antengene, and MSD will provide KEYTRUDA® for the combination portions of the trial.
  • The patient enrollment for the Phase I study of ATG-037 is currently underway in Australia.
  • ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with immune checkpoint inhibitors (ICIs) and chemotherapy agents.

RecycLiCo Battery Materials Reviews 2022 Highlights

Retrieved on: 
Giovedì, Dicembre 15, 2022

SURREY, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. ("RecycLiCo" or "Company"), formerly American Manganese Inc., a battery materials company focused on the development of novel lithium-ion battery recycling and upcycling technologies is pleased to review the following Company highlights from 2022.

Key Points: 
  • SURREY, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. ("RecycLiCo" or "Company"), formerly American Manganese Inc., a battery materials company focused on the development of novel lithium-ion battery recycling and upcycling technologies is pleased to review the following Company highlights from 2022.
  • We are excited for what the future holds as we continue to build next-generation recycling solutions for lithium-ion battery waste."
  • Larry was a visionary leader and a driving force behind the success of RecycLiCo Battery Materials Inc.
  • RecycLiCo Battery Materials Inc. is a battery materials company focused on recycling and upcycling lithium-ion battery waste.

Dropbox Acquires FormSwift

Retrieved on: 
Venerdì, Dicembre 16, 2022

As part of this, were focused on building an end-to-end agreement workflow experience, most recently with simple, secure tools like Dropbox Sign, Dropbox Forms, and DocSend.

Key Points: 
  • As part of this, were focused on building an end-to-end agreement workflow experience, most recently with simple, secure tools like Dropbox Sign, Dropbox Forms, and DocSend.
  • With FormSwift, Dropbox aims to bring FormSwifts vast library of templates from employee onboarding waivers, to rental agreements, to NDAs to its customers, giving them the ability to find, edit, sign and share the documents they need, all from Dropbox.
  • Under the terms of the agreement, Dropbox acquired FormSwift for $95 million in cash subject to customary purchase price adjustments.
  • Dropbox plans to discuss the relevant impact of the FormSwift acquisition on Dropboxs financial metrics during its fiscal Q4 2022 quarterly earnings call.

Antengene Appoints Amily Zhang as its Chief Medical Officer

Retrieved on: 
Giovedì, Dicembre 8, 2022

Before joining Antengene, Dr. Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or "Hengrui Pharma"), including Vice President, Head of Clinical Development - Oncology, Corporate Vice President and Chief Medical Officer for Oncology.

Key Points: 
  • Before joining Antengene, Dr. Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or "Hengrui Pharma"), including Vice President, Head of Clinical Development - Oncology, Corporate Vice President and Chief Medical Officer for Oncology.
  • Dr. Zhang will be based in both New Jersey, the United States, and Shanghai, China.
  • "I am pleased to welcome Amily Zhang as our new Chief Medical Officer.
  • Amily Zhangcommented, "Antengene is emerging as a formidable global biopharmaceutical leader known for its innovation, vibrance, and unique business model.

Antengene Appoints Amily Zhang as its Chief Medical Officer

Retrieved on: 
Mercoledì, Dicembre 7, 2022

Before joining Antengene, Ms. Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or "Hengrui Pharma"), including Vice President, Head of Clinical Development - Oncology, Corporate Vice President and Chief Medical Officer for Oncology.

Key Points: 
  • Before joining Antengene, Ms. Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or "Hengrui Pharma"), including Vice President, Head of Clinical Development - Oncology, Corporate Vice President and Chief Medical Officer for Oncology.
  • Ms. Zhang will be based in both New Jersey, the United States, and Shanghai, China.
  • "I am pleased to welcome Amily Zhang as our new Chief Medical Officer.
  • Amily Zhangcommented, "Antengene is emerging as a formidable global biopharmaceutical leader known for its innovation, vibrance, and unique business model.

LegalOn Technologies, the AI Contract Review Leader, Announces Expansion into the United States

Retrieved on: 
Giovedì, Dicembre 1, 2022

LegalOn Technologies (LegalOn), the leading legal technology company from Japan, announced its expansion into the United States, the largest legal market in the world, and the appointment of Daniel Lewis as US CEO.

Key Points: 
  • LegalOn Technologies (LegalOn), the leading legal technology company from Japan, announced its expansion into the United States, the largest legal market in the world, and the appointment of Daniel Lewis as US CEO.
  • LegalOn has built the worlds leading AI contract review solution for in-house teams and law firms and we are excited to bring our unique solution to the US, says Nozomu Tsunoda, CEO.
  • Daniel Lewis joins LegalOn as US CEO after five years at LexisNexis leading practical guidance businesses serving 100k+ attorneys.
  • LegalOn is the leader in AI contract review software for legal teams.

HydroGraph Appoints Chief Financial Officer

Retrieved on: 
Martedì, Novembre 22, 2022

TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (HG.CN) (the Company or HydroGraph), a commercial manufacturer of high-quality nanomaterials and alternative-energy fuels announced today that Bob Wowk will join the organization as Chief Financial Officer, effective November 21, 2022.Wowk joins the company during a period of significant ramp-up in commercialization, including signing several NDAs with potential customers and shipping to many customers for initial testing.

Key Points: 
  • TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (HG.CN) (the Company or HydroGraph), a commercial manufacturer of high-quality nanomaterials and alternative-energy fuels announced today that Bob Wowk will join the organization as Chief Financial Officer, effective November 21, 2022.Wowk joins the company during a period of significant ramp-up in commercialization, including signing several NDAs with potential customers and shipping to many customers for initial testing.
  • Appointing Bob is part of our overall long-term strategyof enlisting top talent to lead our senior executive team while supporting our application development and commercialization goals to penetrate targeted industries and accelerate sales, said Stuart Jara, a director and Chief Executive Officer of HydroGraph.
  • We are pleased to have him continuing on as Chief Accounting Officer with the company.
  • Joining HydroGraph as CFO represents a once in a life-time opportunity to contribute to the commercialization of a change the world technology and I am excited to be joining an already successful world class management team, saidWowk, the Companys new Chief Financial Officer.